Clinical trials
Completed Anemia, Refractory trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
71 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 7 |
| 2001 | 8 |
| 2002 | 2 |
| 2003 | 5 |
| 2004 | 1 |
| 2005 | 7 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 2 |
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 71 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fred Hutchinson Cancer Center | 9 |
| National Cancer Institute (NCI) | 7 |
| Roswell Park Cancer Institute | 6 |
| Case Comprehensive Cancer Center | 3 |
| Children's Oncology Group | 3 |
| Masonic Cancer Center, University of Minnesota | 3 |
| Memorial Sloan Kettering Cancer Center | 3 |
| Alliance for Clinical Trials in Oncology | 2 |
| Asan Medical Center | 2 |
| Eastern Cooperative Oncology Group | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Anemia, Refractory | 71 |
| Myelodysplastic Syndromes | 55 |
| Anemia, Refractory, with Excess of Blasts | 54 |
| Leukemia, Myelomonocytic, Chronic | 44 |
| Leukemia | 43 |
| Leukemia, Myeloid, Acute | 29 |
| Myeloproliferative Disorders | 28 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 27 |
| Leukemia, Myeloid, Chronic-Phase | 23 |
| Congenital Abnormalities | 22 |
Trials
Showing 1 to 25 of 71. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.